Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
139 participants
INTERVENTIONAL
2021-06-09
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Pharmacokinetics and Safety of AD-208
NCT04214808
Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss
NCT06355856
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
NCT06916793
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
NCT02280603
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT06826196
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Comparator
AD-208 and Placebo of AD-2081
AD-208
PO, Once daily(QD), 24weeks
placebo of AD-2081
PO, Once daily(QD), 24weeks
Placebo Comparator
Placebo of AD-208 and Placebo of AD-2081
placebo of AD-208
PO, Once daily(QD), 24weeks
placebo of AD-2081
PO, Once daily(QD), 24weeks
Experimental Comparator
Placebo of AD-208 and AD-2081
AD-2081
PO, Once daily(QD), 24weeks
placebo of AD-208
PO, Once daily(QD), 24weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-208
PO, Once daily(QD), 24weeks
AD-2081
PO, Once daily(QD), 24weeks
placebo of AD-208
PO, Once daily(QD), 24weeks
placebo of AD-2081
PO, Once daily(QD), 24weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who meet the appropriate criteria according to the classification of hair loss
* Signed informed consent
Exclusion Criteria
* Other exclusions applied
18 Years
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lee S, Kim JE, Lew BL, Huh CH, Kim J, Kwon O, Kim MB, Lee YW, Lee Y, Park J, Kim S, Kim DY, Choi GS, Kang H. Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial. Ann Dermatol. 2025 Aug;37(4):183-190. doi: 10.5021/ad.25.048.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-208P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.